Table 7.

Effects of associating cabergoline with ketoconazole in Cushing’s disease patients.

ID	Sex	Adenoma	Maximum daily (mg) dose of ketoconazole	Maximum weekly dose of cabergoline	Control	Other medications	Side effects	Outcome
7	F	Macro	1,000	3.5 mg	No	Temozolomide and pasireotide	Gastrointestinal effects	RDT
9	F	Normal	1,000	3.5 mg	No	Mitotane	AI symptoms	Adrenalectomy
10	F	Macro	1,200	3 mg	Yes	–	–	Medications maintained
14	F	Macro	800	1.5 mg	No	–	Elevation of transaminases	RDT
15	F	Micro	1,200	3 mg	No	Mitotane	–	RDT
21	F	Normal	600	2 mg	Yes	–	Gastrointestinal symptoms	Adrenalectomy
26	F	Macro	400	2 mg	No	–	–	RDT
28	M	Macro	1,200	4.5 mg	No	Pasireotide	Hyperglycemia, hypogonadism, and hypokalemia	RDT

AI, adrenal insufficiency; ND, no data; RDT, radiotherapy.